Financial Performance - Lucid Group produced 3,386 vehicles in Q4 2024 and delivered 3,099 vehicles during the same period, with total production for the year at 9,029 vehicles and deliveries at 10,241 vehicles, marking a 79% increase in Q4 deliveries and a 71% increase in annual deliveries compared to 2023 [2][8] - The company reported Q4 revenue of $234.5 million and annual revenue of $807.8 million, with total liquidity at approximately $6.13 billion at the end of the quarter [3][8] - The GAAP net loss per share was $(0.22) for Q4 and $(1.25) for the full year 2024, while the non-GAAP net loss per share was $(0.22) for Q4 and $(1.04) for the full year 2024 [8] Production Guidance - Lucid announced its 2025 annual production guidance of approximately 20,000 vehicles, indicating a significant ramp-up in production compared to 2024 [2][8] Leadership Transition - Peter Rawlinson stepped down as CEO and will serve as Strategic Technical Advisor to the Chairman of the Board, while Marc Winterhoff, previously COO, has been appointed as Interim CEO [4][8] Operational Highlights - The company experienced significant momentum in 2024 with four consecutive quarters of record deliveries and made substantial progress in improving gross margins and managing operating expenses [4][8]

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has received written notification from the Listings Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.As previously disc ...

Shares of Lucid Group (LCID -9.64%) plunged below $3 Monday, and were down by 10% as of 2:30 p.m. ET. A significant analyst downgrade appears to have triggered the sell-off. Why is this analyst so bearish about Lucid stock?Redburn Atlantic analyst Tobias Beith downgraded Lucid stock to sell from neutral, slashing his price target from $3.50 a share to only $1.13 per share. That new target is 63% below the electric vehicle (EV) maker's closing price Friday.Although Beith believes it won't be easy for Lucid's ...

Is the struggling electric vehicle maker a turnaround play?Lucid Group (LCID -7.35%) has disappointed many investors since its public debut in July 2021. The maker of luxury electric sedans went public by merging with a special purpose acquisition company (SPAC), and it opened at $25.24 on its first day.Its stock more than doubled to its record closing price of $55.52 just four months later, but it now trades at about $3 a share. Let's see why Lucid's stock crashed and burned, and if it's worth buying as a ...

Lucid (LCID -7.85%) stock is heading lower in Friday's trading amid a day of big sell-offs for the broader market. The electric vehicle (EV) specialist's share price was down 7.6% as of 3:40 p.m. ET. Meanwhile, the S&P 500 (^GSPC -1.73%) was down 1.7%, and the Nasdaq Composite (^IXIC -2.25%) was down 2.2%.Lucid is retreating today due to a combination of catalysts. In addition to bearish macroeconomic indicators, the company's share price is likely also being pressured by guidance from Rivian -- another pla ...

Lucid Group (LCID) closed the latest trading day at $3.31, indicating a -1.78% change from the previous session's end. The stock trailed the S&P 500, which registered a daily loss of 0.43%. On the other hand, the Dow registered a loss of 1.01%, and the technology-centric Nasdaq decreased by 0.47%.Heading into today, shares of the an electric vehicle automaker had gained 26.22% over the past month, outpacing the Auto-Tires-Trucks sector's loss of 8.96% and the S&P 500's gain of 2.6% in that time.The investme ...

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3] Partnership Announcement - Lucid Diagnostics has entered into its first concierge medicine contract with LEAA Health, allowing LEAA Health's membership-based patients access to EsoGuard esophageal precancer testing on a cash-pay basis. This partnership aims to enhance personalized care services [1][2] Market Potential - The concierge medicine market in the United States is projected to reach $10.9 billion by 2032, indicating a growing demand for personalized, prevention-focused healthcare services [2] Product Offering - EsoGuard is described as a groundbreaking approach to esophageal precancer detection, enabling early identification of potential issues when intervention can be most effective. The test is part of LEAA Health's enhanced personalized care offerings [2] Strategic Goals - Lucid aims to drive contractually guaranteed revenue through its cash-pay program targeting concierge medicine, while also working to secure Medicare and commercial coverage for its products [2]

Lucid Group (LCID) is slated to release fourth-quarter 2024 results on Feb. 25, after market close. The Zacks Consensus Estimate for the to-be-reported quarter is pegged at a loss of 26 cents a share on revenues of $225.5 million. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The loss per share estimate for the fourth quarter of 2024 has remained unchanged over the past 90 days. The bottom-line projection indicates a year-over-year improvement of 10.3%. The Zacks Consensus Estimate ...

Lucid Motors (NASDAQ: LCID) has surged to a five-month high, trading at $3.495 on February 18, 2025, after gaining 8% on the day and an impressive 28% over the past week.This marks a significant recovery from its multi-month lows, with LCID reaching levels not seen since September 2024. The luxury electric vehicle (EV) maker has faced a turbulent journey since its 2021 IPO, struggling with missed production targets, financial losses, and ongoing investor concerns over stock dilution. Lucid six-month price c ...

It's no secret that Lucid Group (LCID 1.96%) has faced its fair share of speed bumps already. The automaker has driven through increased competition, price wars, supply chain issues, recalls, and software issues -- just to name a few.But the young electric vehicle (EV) manufacturer finally broke through the noise and turned in a solid 2024. Already, however, it seems that 2025 could bring yet another speed bump. Should investors worry?Total deliveries are upInvestors received a breath of fresh air in 2024 a ...